Abstract 876P
Background
OGCT and SCST are rare ovarian neoplasms that however affect a disproportionally high number of young women. Little is known about the impact of surgical and adjuvant management of these patients on sexuality. This analysis focused on the effect of fertility-sparing surgery on pleasure and discomfort during sexual intercourse and global quality of life (QoL) in women with OGCT and SCSCT.
Methods
OGCT and SCST survivors of the Current Ovarian geRm cell and SEx cord stromal Tumour Treatment strategies database of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) were contacted and completed a global QoL (EORTC QLQ-C30), a sexuality (SAQ Fallowfield) and an anxiety and depression (HADS) questionnaire. Descriptive analyses and multivariate logistic regressions were conducted.
Results
This study included 103 patients with SCST and 46 with OGCT, who completed the SAQ. These participants were younger (median age 50 vs 55 yrs), had less likely chemotherapy and disease recurrence than the 117 patients of the CORSETT database who did not complete the SAQ (p < 0.001). 88 patients (54 %), who responded to the SAQ, were sexually active with a mean ‘pleasure’ score of 10.1 (scale 0-18, SD 4.0) and ‘discomfort’ score of 4.3 (scale 1 - 6, SD 1.9). For both subscales, higher values indicate more positive outcomes. Main reasons for sexual inactivity were “no interest in sex”, “no partner” and “physical problems”. Sexual activity was higher with fertility-sparing surgery (OR 3.0, p=0.001) in the non-adjusted analysis. When adjusting for FIGO stage, histology, age, chemotherapy and disease recurrence, the OR was 2.0 (p=0.15). ‘Pleasure’ and ‘discomfort’ scores did not differ significantly between fertility-sparing vs non-sparing surgery. Mean global QoL was 71 (0-100) and also did not show any significant difference in relation to the surgical approach.
Conclusions
Sexual inactivity was high with 46% in a group of comparably young patients and was associated with non-fertility-sparing surgery. However, in sexually active SCST or OGCT survivors, there was no evidence that surgical techniques had an impact on the quality of patient’s sexual life.
Clinical trial identification
IRB 513/13.
Editorial acknowledgement
Legal entity responsible for the study
Arbeitsgemeinschaft Gynäkologische Onkologie (AGO).
Funding
Celgene.
Disclosure
A. Hasenburg: Honoraria (self): AstraZeneca; Honoraria (self): MedConcept; Honoraria (self): Pfizer; Honoraria (self): Promedicis GmbH; Honoraria (self): Roche Pharma; Honoraria (self): Streamedup!GmbH; Honoraria (self): Tesaro; Advisory/Consultancy: Pharma Mar; Advisory/Consultancy: Pierre Fabre; Honoraria (institution): Roche Pharma; Honoraria (institution): Tesaro; Research grant/Funding (institution): Celgene. E. Braicu: Honoraria (self): Roche; Honoraria (self): AstraZeneca; Honoraria (self): Tesaro; Honoraria (self): Clovis; Honoraria (self): GSK; Honoraria (self): AbbVie; Honoraria (self): Genmab / Seattle Genetics; Honoraria (self), Honoraria (institution): MSD; Honoraria (self), Honoraria (institution): Incyte; Honoraria (institution): Bayer; Honoraria (institution): Roche Diagnostics. S. Singer: Honoraria (self): BMS; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Lilly; Honoraria (self): Pfizer. A. du Bois: Honoraria (self): Roche; Honoraria (self): AstraZeneca/MSD; Honoraria (self): Clovis; Honoraria (self): GSK/Tesaro; Honoraria (self): Biocad; Honoraria (self): Genmab/Seattle Genetics; Honoraria (self): Pfizer. T. Link: Honoraria (self): MSD; Honoraria (self): Amgen; Honoraria (self): Pfizer; Honoraria (self): Novartis; Honoraria (self): Teva; Honoraria (self): Tesaro; Honoraria (self): Roche; Honoraria (self): Clovis. F. Heitz: Honoraria (self): Roche; Honoraria (self): AstraZeneca; Honoraria (self): Clovis; Honoraria (self): Molecular Health; Honoraria (self): GSK/Tesaro. F. Trillsch: Honoraria (self): AstraZeneca; Honoraria (self): Clovis; Honoraria (self): Medac; Honoraria (self): Pharma Mar; Honoraria (self): Roche; Honoraria (self): Tesaro. P. Harter: Honoraria (self), Research grant/Funding (self): Roche; Honoraria (self), Research grant/Funding (self): AstraZeneca; Honoraria (self): Sotio; Honoraria (self), Research grant/Funding (self): Tesaro; Honoraria (self): Stryker; Honoraria (self): Zai Lab; Honoraria (self): MSD; Honoraria (self): Clivis; Honoraria (self), Research grant/Funding (self): Public funding (ASCO, DKH, DFG); Honoraria (self): Immunogen; Research grant/Funding (self): GSK; Research grant/Funding (self): Boehringer Ingelheim; Research grant/Funding (self): Medac; Research grant/Funding (self): Genmab. P. Wimberger: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Roche; Honoraria (self), Research grant/Funding (institution): AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Amgen; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): MSD Sharp & Dohme (Merck US); Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Novartis; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Honoraria (self), Advisory/Consultancy: Tesaro; Honoraria (self): PharmaMar; Honoraria (self): Teva. M. Klar: Advisory/Consultancy: Tesaro/GSK. All other authors have declared no conflicts of interest.